• Alaunos Therapeutics priced a registered direct offering of 380,469 common shares, raising about USD 1.12 million gross.
• Deal includes pre-funded warrants for up to 386,654 shares, priced at USD 1.46 per share.
• Closing expected around Sept. 21, 2026, subject to customary conditions.
• Net proceeds earmarked for working capital, corporate purposes.
• Dawson James Securities serving as sole placement agent.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alaunos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609180900PRIMZONEFULLFEED9829550) on September 18, 2026, and is solely responsible for the information contained therein.